Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background—: Recent proposals suggest that risk-stratified analyses of clinical trials be routinely performed to better enable tailoring of treatment decisions to individuals. Trial data can be stratified using externally developed risk models (eg, Framingham risk score), but such models are not always available. We sought to determine whether internally developed risk models, developed directly on trial data, introduce bias compared with external models. Methods and Results—: We simulated a large patient population with known risk factors and outcomes. Clinical trials were then simulated by repeatedly drawing from the patient population assuming a specified relative treatment effect in the experimental arm, which either did or did not vary according to a subject’s baseline risk. For each simulated trial, 2 internal risk models were developed on either the control population only (internal controls only) or the whole trial population blinded to treatment (internal whole trial). Bias was estimated for the internal models by comparing treatment effect predictions to predictions from the external model. Under all treatment assumptions, internal models introduced only modest bias compared with external models. The magnitude of these biases was slightly smaller for internal whole trial models than for internal controls only models. Internal whole trial models were also slightly less sensitive to bias introduced by overfitting and less sensitive to falsely identifying the existence of variability in treatment effect across the risk spectrum compared with internal controls only models. Conclusions—: Appropriately developed internal models produce relatively unbiased estimates of treatment effect across the spectrum of risk. When estimating treatment effect, internally developed risk models using both treatment arms should, in general, be preferred to models developed on the control population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simulation study of the number of events per variable in logistic regression analysis
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00236-3 · Cited by 9,655 · cited 1×
“Our base case trial scenarios were designed so that the ratio of EPV included in the model was slightly >1:10 to limit bias due to overfitting.(21) In real-world scenarios, it may be that there are a large number of potentially important predictors or a relatively small number of outcomes, and thus the models will be…”
BackgroundGrundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Subgroup analysis in randomised controlled trials: importance, indications, and interpretation
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17709-5 · Cited by 942
Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M., & Cook, N. R. (2008) · Circulation · doi:10.1161/circulationaha.108.814251 · Cited by 841
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A. (2010) · Trials · doi:10.1186/1745-6215-11-85 · Cited by 504
Self-citationDorresteijn, J. A. N., Visseren, F. L. J., Ridker, P. M., Wassink, A. M. J., Paynter, N. P., Steyerberg, E. W., van der Graaf, Y., & Cook, N. R. (2011) · BMJ · doi:10.1136/bmj.d5888 · Cited by 177 · cited 1×
“tempting to use the randomized controlled trial data to design a baseline risk model and examine treatment effect across risk defined by that internal risk model, an approach recently applied to the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study.(17) Y…”
Method
Cited by
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects
Kent, D. M., Steyerberg, E., & van Klaveren, D. (2018) · BMJ · doi:10.1136/bmj.k4245 · Cited by 479
Self-citationThe Predictive Approaches to Treatment effect Heterogeneity (PATH) statement
Kent, D. M., Paulus, J. K., van Klaveren, D., D'Agostino, R., Goodman, S., Hayward, R., Ioannidis, J. P. A., Patrick-Lake, B., Morton, S., Pencina, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m18-3667 · Cited by 469
Self-citationIwashyna, T. J., Burke, J. F., Sussman, J. B., Prescott, H. C., Hayward, R. A., & Angus, D. C. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2125cp · Cited by 276
Self-citationKessler, R. C., van Loo, H. M., Wardenaar, K. J., Bossarte, R. M., Brenner, L. A., Cai, T., Ebert, D. D., Hwang, I., Li, J., de Jonge, P., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.198 · Cited by 254
Basu, S., Sussman, J. B., Berkowitz, S. A., Hayward, R. A., & Yudkin, J. S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30221-8 · Cited by 206
Self-citation
Metadata
- Authors
- Burke, J. F., Hayward, R. A., Nelson, J. P., & Kent, D. M.
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2014-01
- Volume
- 7
- Issue
- 1
- Pages
- 163-169
- ISSN
- 1941-7705 (ISSN-L)
- 1941-7713
- OpenAlex
- W2107053960
- Cited by
- 86
- References
- 8
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials. https://app.cochat.ai/papers/10.1161/circoutcomes.113.000497
- The paper
- Burke, J. F., Hayward, R. A., Nelson, J. P., & Kent, D. M. (2014). Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.113.000497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.